ACM approves merger between BERGMAN CLINICS and NL HEALTHCARE CLINICS

NPM Capital

Specialised clinics offer superior care at competitive rates

The Netherlands Authority for Consumers & Markets green-lit the merger between Bergman Clinics and NL Healthcare Clinics (NLHCC) on 17 December 2018. With their specialised clinics, Bergman Clinics and NLHCC are leaders in the Netherlands in the medical disciplines of ophthalmology, orthopaedics, dermatology, plastic surgery and several other specific types of insured specialised medical care. The combined clinics seek to offer high-quality patient-centred care at competitive prices at facilities throughout the Netherlands. Following a transitional stage, the merged healthcare chains will start operating under the name Bergman Clinics. Newly appointed CEO Hans van der Heyden will assume office on the official completion of the merger of the two clinics in early January.

Once the merger is completed, the consolidated Bergman Clinics will be the market leader in treatments for health-insurance-covered hip, knee, shoulder, foot/ankle, back and eye conditions and plastic surgery procedures. The new Bergman Clinics also provides specialised care for skin conditions, gastrointestinal disorders, and pelvic floor dysfunction for women.

The new group will operate a 52-branch nationwide network of clinics with consolidated revenue of approximately €230 million and around 1,500 employees. The group expects to be able to create new jobs in the coming years by expanding existing clinics and opening new ones. The company also aims to drive innovation in the Dutch healthcare sector.

Discerning and selective clients

The merger comes at a time when Dutch consumers are becoming progressively more discerning and selective in their choices, and this certainly extends to medical services. Both patients and health insurance companies are increasingly prioritising proven quality of treatments, cost management, short waiting times and the overall quality of services provided. The specialised Bergman Clinics are able to provide high quality at competitive rates, which they combine with a client-focused approach, where service and client experience are vital.

Bergman Clinics will accommodate the group’s central support services at the Naarden site. Hans van der Heyden will chair the group’s Executive Board and head up the management team. For clients and referrers such as general practitioners, everything will remain unchanged in terms of day-to-day interaction with the clinics.

New Bergman Clinics CEO Hans van der Heyden is an experienced leader who previously held managerial positions at Procter & Gamble and other companies, as well as being a member of the global management of GrandVision. After being in charge of the Benelux market for eight years, he served as CEO of GrandVision USA, during which time he managed the integration of the For Eyes optical retail chain.

Current CEO Bart Malenstein will remain with the company as an Executive Board member for some time on completion of the merger, and both the Malenstein family and NL Healthcare Clinics shareholder NPM Capital – a subsidiary of family business SHV – will remain shareholders in the new company.

Current Bergman Clinics CEO Bert Malenstein: “We are ready to leverage the opportunities offered by this merger together. With our pooled resources, treatment teams will be able to focus their attention even more closely on their specialisation. There will also be more room to invest in technological innovation, digitalisation and training and education. When we first announced this merger back in September 2018, the feedback we received was very positive. It’s up to us now to prove that greater focus and the pooling of our resources lead to more efficient cost management and improved results. In appointing Hans van der Heyden, we have brought on board a strong leader who can add value through his experience, both in the integration process and in our objective to keep improving client experiences. Hans has worked with consumer brands for many years and is familiar with the healthcare industry. This is the perfect combination for the position of CEO at Bergman Clinics.”

Rutger Ruigrok, Managing Director at NPM Capital: “The scale, efficiency, professionalism and client focus of the merged organisation will strengthen our clinics’ brand and performance and will enable them to make an even more valuable contribution to the Dutch healthcare landscape.”

 

Categories: News

Tags:

Maincare acquisition of Anticyclone

Montagu

Maincare solutions announces the acquisition of Anticyclone, a leading French provider of speech recognition and document management software for hospitals.

Anticyclone was founded in 2004 and has experienced rapid growth on the back of i) its joint offer which combines best-of-breed speech recognition and document management and ii) strong demand for software optimising workflow management in public hospitals.  It now serves ~100 healthcare institutions and has a total user-base of 22,000 medical professionals.

Maincare and Anticyclone have been partners since 2009.  The acquisition will enable Maincare to embed a best-of-breed solution in its new software platform and drive commercial synergies across the business.  Anticyclone will become a new business unit within the Group.

Categories: News

Tags:

Acacia Pharma reports positive cardiac safety data for BARHEMSYS™

GIlde Healthcare

Cambridge, UK and Indianapolis, US – Acacia Pharma (EURONEXT: ACPH) announces results from its latest study of BARHEMSYS™, its anti-emetic currently under FDA review for the management of post-operative nausea & vomiting (PONV).

The study did not find a significant risk for heart rhythm disturbances (arrhythmias) at the highest proposed dose of BARHEMSYS, given alone or in combination with intravenous ondansetron, a widely used PONV therapy with a known effect on the heart trace.

The data confirm that a single 10 mg dose of BARHEMSYS, which has previously been shown to reduce PONV in clinical trials, will not have a clinically significant effect on the QTc interval, part of the ECG trace which is an important indicator of cardiac risk, even when given with ondansetron. If approved, BARHEMSYS is likely to be given to many patients also receiving ondansetron.

In 30 healthy volunteers, the average maximum effect on the QTc interval of a single 10 mg dose of BARHEMSYS, infused over one minute, was 5.2 milliseconds (90% confidence interval 3.53-6.96 milliseconds). When a standard 4 mg dose of IV ondansetron was given at the same time, the average maximum effect was 7.3 milliseconds (90% confidence interval 5.48-9.16 milliseconds). The internationally agreed threshold level of regulatory concern for serious arrhythmias, such as torsade de pointes, is a mean effect on QTc of 10 milliseconds.

The randomised, double-blind, placebo-controlled, cross-over study, conducted in a specialist Phase 1 trials unit in London, UK, also demonstrated that a second 10 mg dose of BARHEMSYS, given two hours after the first, had a similar pharmacokinetic profile and did not significantly affect the QT or clinical safety profile of the drug. No serious adverse events were reported in the trial and there was no material difference in safety profile between BARHEMSYS (with or without concomitant ondansetron) and placebo.

The most common adverse events were infusion site pain/discomfort, which occurred in eight subjects (28%) with BARHEMSYS alone, nine subjects (30%) with BARHEMSYS plus ondansetron and 12 subjects (40%) with placebo; and headache, which occurred in four subjects (14%) with BARHEMSYS alone, three subjects (10%) with BARHEMSYS plus ondansetron and two subjects (7%) with placebo.

BARHEMSYS is currently under review by FDA for the proposed indications of the treatment of established PONV, whether or not prior prophylaxis was given, and the prevention of PONV, alone or in combination with other antiemetics, with a target action date of May 5, 2019.

 

About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. Acacia Pharma has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.
Acacia Pharma’s lead project, BARHEMSYS™ for post-operative nausea & vomiting (PONV), has generated positive results in four Phase 3 clinical studies. A New Drug Application (NDA) for BARHEMSYS is under review by the US Food and Drug Administration (FDA). Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV), has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma is based in Cambridge, UK and its US operations are centered in Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH.
Website: www.acaciapharma.com

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market.
Website: www.gildehealthcare.com

Gilde Healthcare II is supported by the European Communities Growth and Employment Initiative, MAP – ETF Start-up Facility.

Categories: News

Tags:

Altor divests majority stake in Orchid Orthopedic Solutions to Nordic Capital

Altor

On January 21, Altor Fund III (“Altor”) announced that it has agreed to divest the majority of its current holding in Orchid Orthopedic Solutions (“Orchid”) to Nordic Capital Fund IX (“Nordic Capital”). Altor will retain a significant minority holding in the company.

Altor has been the majority owner of Orchid since 2011. Headquartered in Holt, Michigan, Orchid is a world leader in the design and manufacture of implants to the global orthopedic market. Orchid’s leading offerings span hip, knee, trauma, extremity and spinal implant products, as well as single-use and multi-use complex instruments used in implant related surgical procedures.

As a strategic partner to the leading global medical device OEMs, Orchid offers solutions in product and procedure design and possesses the full range of manufacturing processes required to produce finished, packaged products. The Company serves a global customer base from its 12 manufacturing sites in the US, UK, Switzerland and China. Orchid innovates continually to provide differentiated processes yielding unique products, while simplifying its customers’ supply chains, delivering outstanding quality and offering end-to-end solutions benefitting from the broadest implants portfolio in the market.

The orthopedic implant market benefits from strong secular growth driven by larger and increasingly active elderly populations, obesity, medical advancements and increased access to surgical orthopedic care. As a leader in the industry, Orchid is ideally positioned to capitalize on this demand growth while helping its customers become more competitive.

“We are proud of what we have achieved together with the management team during these eight years where we have built Orchid into a world leading supplier of design and manufacturing solutions for the rapidly growing global orthopedic implant market. During Altor’s ownership, Orchid has developed into a true global company serving global customers with innovative end-to-end manufacturing solutions. We are excited to see Nordic Capital as the new main owner with Altor continuing the journey as a significant minority shareholder since we have continued strong belief in Orchid’s strong management team, unique position and the attractive long-term industry fundamentals. Together we are fully committed to support Orchid’s management team in realizing the company’s growth strategy” says Claes Ekström, Chairman of Orchid and Senior Advisor at Altor Equity Partners AB.

Orchid’s current management team, led by CEO Jerry Jurkiewicz, will continue to lead the Company, building on its strong track record of both organic and acquisitive growth.

“We are very proud of our achievements during Altor’s tenure as our majority owner. We have transformed Orchid from a US contract manufacturer to the leading global orthopedic implants design and manufacturing partner in the world. We focused on satisfying our customers with a broad array of innovative implants procedure solutions built upon manufacturing sites dedicated to delivering operational excellence. We are humbled by Altor’s renewed commitment to Orchid in partnership with Nordic Capital” says Orchid CEO Jerry Jurkiewicz.
The parties have agreed not to disclose financial details of the transaction, which remains subject to customary regulatory approvals.

Media contacts
Tor Krusell, Head of Communications at Altor
Tel: +46 70 543 87 47
e-mail: tor.krusell@altor.com

About Orchid Orthopedic Solutions
Orchid is a world leader in orthopedic medical device solutions, providing design and manufacturing services globally. As a strategic partner, Orchid has the capability of providing entire implant procedure and product design services, as well as, complete single source manufacturing. Orchid has the broadest portfolio in the industry, ranging from design and development through finished goods manufacturing and packaging, improving customers’ supply chains and adhering to the highest quality standards in the industry. Orchid specializes in implants, single use instruments and innovative technologies within joint reconstruction, hips, knees, spine, trauma, extremities and dental. For further information, please see www.orchid-ortho.com

About Altor
Since inception, the family of Altor funds has raised some EUR 5.8 billion in total commitments. The funds have invested in excess of EUR 4.2 billion in more than 40 companies. The investments have been made in medium sized, predominantly Nordic, companies with the aim to create value through growth initiatives and operational improvements. Among current and past investments are ByggMax, Carnegie Investment Bank, Dustin, Dynapac, Helly Hansen, Lindorff and SATS ELIXIA. For more information visit altor.com.

Categories: News

Tags:

3i announces sale of OneMed generating proceeds of c. £100 million

3I

 

3i Group plc (“3i”), and funds managed by 3i, have entered into a sale and purchase agreement to sell their investment in OneMed, the leading medical supplies distributor in Northern Europe, to Nalka Invest AB.

Proceeds to 3i will be c. £100m. The transaction is expected to complete in March 2019, subject to customary antitrust approvals.

3i invested in OneMed in 2011. During 3i’s ownership, the company successfully strengthened its market positions in Sweden, Denmark and Finland and built its international footprint through three strategic acquisitions in the Netherlands and a major expansion in Norway.

For further information, contact:
3i Group plc
Silvia Santoro
Investor enquiries
Kathryn van der Kroft
Media enquiries
Tel: +44 20 7975 3258
Email: silvia.santoro@3i.com
Tel: +44 20 7975 3021
Email: kathryn.vanderkroft@3i.com

Categories: News

Tags:

Smile Brands and DecisionOne Dental Announce Strategic Partnership

Gryphon Investors

Irvine, CA – January 7, 2019 —

Smile Brands Incannounced today it has made a strategic investment in support of DecisionOne Dental Partners based in Schaumburg, Illinois. The investment will help fund DecisionOne’s continued growth and acquisitions throughout Chicagoland and neighboring states. DecisionOne Dental Partners management will continue to lead and operate the business.

Smile Brands Inc. is a leading dental support organization (DSO) that provides business support services to over 400 locations across 17 states. Smile Brands is able to provide DecisionOne significant expansion capital as well as access to additional business support services. CEO Dr. AJ Acierno of DecisionOne and CEO Steve Bilt of Smile Brands realize the future of mid-market DSOs is to have an investment and business support partner like Smile Brands who has services that can help accelerate growth while continuing to meet the needs of providers and patients.

DecisionOne was founded in 2011 by two brothers, Dr. AJ Acierno and Dr. Mike Acierno. It is one of the most respected and fastest growing dental support organizations in the U.S. with approximately 30 affiliated practices in the Chicago area. By blending the values of a solo practitioner dental office with the business efficiencies of larger group practices, DecisionOne has created a proven partnership model that puts patients first while helping providers navigate the increasing complexity of the dental landscape.

“Many DSOs help remove day to day management headaches allowing providers to focus on clinical excellence. At DecisonOne, we go beyond standard DSO administrative support by building offices around our doctors instead of simply inserting providers into cookie cutter offices,” explains Dr. AJ Acierno. “This approach allows us to create individual office cultures that result in lasting patient relationships. We believe strongly that building patient relationships based on trust is the key to guaranteeing access to care and making patients better.”

The world of dentistry has changed dramatically over the past several decades. Dental students are graduating with high amounts of debt, technologic advancements require higher overhead and payment administration is increasingly complex. More and more providers are looking to affiliate with a dental support organization, but finding the right fit is imperative. Smile Brands CEO, Steve Bilt understands the importance of there being a strong cultural connection in any partnership.

“Today there are hundreds of DSOs and thousands of group practices in the U.S.,” says Bilt, “Each group has its unique affiliation model in terms of financial compensation, business support and management processes, but the success of a partnership comes down to whether the groups share a common set of values. Our investment behind DecisionOne is as much about shared values as it is about business expansion. I am confident that Drs. AJ, Mike and the rest of the DecisionOne team will further our mission of delivering Smiles for Everyone®.”

Dr. Mike Acierno, Chief Dental Officer, insists that clinical autonomy is key in a patient-first delivery model. “After dental school, I went into private practice and AJ took the DSO path,” explains Mike. “That gives us a unique perspective on the industry and how to improve the lives of our patients, team members and providers. When it came time to find a partner, we needed to find someone as committed to our patient care model as we are.”

About Smile Brands 
Based in Irvine California, Smile Brands Inc. is one of the largest providers of support services to dental groups in the United States. Smile Brands provides expansion capital and access to support services to independent dental groups and DSOs. The organization delivers comprehensive business support services through exclusive long term agreements with affiliate dental groups, so dentists can spend more time caring for their patients and less time on the administrative, marketing, and financial aspects of operating a dental practice. Smile Brands supports over 400 Bright Now!® Dental, Monarch Dental®, Castle Dental®, A+ Dental Care, OneSmile Dental, Johnson Family Dental, P3 Dental Group, and DecisionOne Dental offices in 17 states, including Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Maryland, Nevada, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Virginia, and Washington. Smile Brands is a portfolio company of Gryphon Investors, a leading middle-market private equity firm based in San Francisco, CA. For more information, visit www.smilebrands.com.

About DecisionOne Dental Partners 
DecisionOne Dental is a network of carefully curated dental professionals who value personal doctor-patient relationships and high quality of patient care. Over the last decade, the growing complexity of the dental sector has diluted doctors’ focus and led to a reduction in the perception of patient care and trust. DecisionOne Dental Partners was founded by brothers Dr. AJ and Dr. Mike Acierno, both practicing family dentists, who believe dentistry can thrive locally while adhering to the core values that support patients above all else. With approximately 30 current locations, DecisionOne is the fastest growing dental group in Illinois. The Chicago Tribune named them one of the top midsized workplaces in the Chicago area for 2018, plus Acierno Dental in Schaumburg was recently featured in Chicago magazine’s “2018 Top Doctors” issue named as a top Chicagoland dental practice. For more information about DecisionOne Dental or to find a dentist, visit www.decisiononedental.com.

Contacts

 

Categories: News

Tags:

TA Associates Announces Investment in Behavioral Health Works

TA associates

BOSTON and ANAHEIM, CA – TA Associates, a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Behavioral Health Works (“BHW”), a behavioral health services provider specializing in therapy and ancillary services for children with autism spectrum disorder and related disorders. Financial terms of the transaction were not disclosed.

Established in 2009, BHW works with families, schools and other professionals to offer comprehensive therapy services based on the principles of Applied Behavioral Analysis (“ABA”). Care is delivered by therapists at home, in schools and in regional centers. The company provides care across 11 states, serving approximately 1,800 clients.

“We believe BHW has become a leader in providing therapy and behavioral health services to individuals affected by autism as a result of the company’s commitment to clinical quality and outcomes measurement,” said Emily C. McGinty, a Principal at TA Associates who will join the Behavioral Health Works board of directors. “We are thrilled to partner with Dr. Robert Douk and the team of knowledgeable and passionate clinical and administrative professionals at BHW. We look forward to working closely with the team to help expand access to services to additional families in need.”

“Since our founding, we have strived to provide children with autism with research-based therapeutic methods to improve both basic and complex skills that permit them to lead quality and independent lives,” said Dr. Robert Douk, Founder and Chief Executive Officer of Behavioral Health Works. “As one of the most longstanding and respected investors within the healthcare industry, we believe that TA Associates will help us accelerate our strategy and reach more children who need our services. We welcome TA to the BHW family and are very excited to begin collaborating with their team to support our company in the next phase of its growth.”

“As autism prevalence continues to grow, it is critical that treatment providers have the necessary resources in place to support affected individuals and families,” said Jennifer M. Mulloy, a Managing Director at TA Associates who will also join the Behavioral Health Works board of directors. “We look forward to continuing to support and build a best in class team of clinicians to help meet the increasing demand.”

Kirkland & Ellis LLP provided legal counsel and Deloitte LLP served as financial advisor to TA Associates. Lewis Brisbois Bisgaard & Smith LLP provided legal counsel, Moss Adams served as financial advisor and Opus Bank provided advisory services to Behavioral Health Works.

About Behavioral Health Works
Behavioral Health Works helps individuals with autism and other developmental disabilities reach their potential by working collaboratively with families, schools and relevant professionals. BHW’s treatment approach is rooted in Applied Behavior Analysis (ABA) with emphasis on individualized programs, focusing on each person’s strengths and challenges. Each of BHW’s programs share the common goal of teaching individuals the necessary tools to obtain a better quality of life and to lead more independent lives. More information can be found at www.bhwcares.com.

About TA Associates
TA Associates is one of the largest and most experienced global growth private equity firms. Focused on five target industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in growth companies. TA has raised $24 billion in capital since its founding in 1968 and is committing to new investments at the pace of $2 billion per year. The firm’s more than 85 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA Associates can be found at www.ta.com.

Categories: News

Tags:

Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement

KKR

BRISBANE, Calif.–(BUSINESS WIRE)–Jan. 4, 2019– Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading global investment firm.

“The addition of the KKR loan financing to Aimmune’s capital resources is expected to fully fund the commercialization of AR101, an investigational biologic oral immunotherapy for the treatment of peanut allergy,” said Eric Bjerkholt, Chief Financial Officer of Aimmune Therapeutics. “In addition, this financing secures resources to support the continued advancement of our pipeline of additional food allergy treatments, including the Phase 2 trial of AR201 for egg allergy, which is anticipated to commence this year.”

In December 2018, Aimmune submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration(FDA) for AR101 for the treatment of peanut allergy in children and adolescents ages 4–17 years based on data from the landmark Phase 3 PALISADE trial, which met its primary and key secondary endpoints, and from additional ongoing and completed AR101 clinical trials. The FDA has granted Breakthrough Therapy Designation to AR101 for the desensitization of peanut-allergic patients 4–17 years of age.

The loan agreement provides Aimmune with an up to $170 million term loan in three tranches. Forty million dollars was funded at close, with $85 million to follow upon FDA approval of AR101 and satisfaction of other customary borrowing conditions, and $45 million at the company’s option in 2020 upon the satisfaction of certain borrowing conditions. The loan can be prepaid at Aimmune’s discretion, at any time, subject to prepayment fees. Further information with respect to the term loan is set forth in a Form 8-K filed by Aimmune with the Securities and Exchange Commission on January 4, 2019.

Aimmune reported September 30, 2018, cash, cash equivalents and short-term investments of $255 million. With the $98 million equity investment from Nestlé Health Science announced in November 2018 and the $170 million KKR loan, assuming full borrowings under all tranches, Aimmune’s capital resources as of September 30, 2018, would have exceeded $500 million.

For KKR, the investment is part of the firm’s Health Care Royalty and Income strategy, which is focused on providing non-dilutive capital to companies for which KKR can help reach scale and achieve strategic objectives.

“Aimmune is leading the way in meeting the critical, growing need to offer treatment to the millions of people affected by food allergies,” said Emily Janvey, M.D., Head of Health Care Royalty and Income strategy at KKR. “We’re proud to help support Aimmune’s important work, especially as the company prepares to launch what could be the world’s first approved medical treatment for peanut allergy.”

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™ is AR101. Aimmune intends to submit a regulatory filing for marketing approval of AR101 in Europe during the first half of 2019 based on data from Aimmune’s pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. Aimmune has filed an IND application for its second product, AR201, for the treatment of egg allergy and intends to start a randomized Phase 2 clinical trial in the first half of 2019. For more information, please see www.aimmune.com.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations regarding the timing and availability of the full amount of proceeds under the loan agreement; Aimmune’s expectations regarding the sufficiency of its cash resources; Aimmune’s expectations regarding the potential benefits of AR101; Aimmune’s expectations regarding the potential commercialization of AR101, including the timing of a potential approval of AR101; Aimmune’s expectations on the timing of initiating a Phase 2 clinical trial for AR201; Aimmune’s expectations on regulatory submissions for marketing approval of AR101 for peanut allergy in Europe; and Aimmune’s expectations regarding potential applications of the CODIT™ approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the satisfaction of closing conditions for each subsequent tranche of the loan agreement; the expectation that Aimmune will need additional funds to finance its operations; Aimmune’s or any of its collaborative partners’ ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; Aimmune’s reliance on third parties for the manufacture of Aimmune’s product candidates; possible regulatory developments in the United States and foreign countries; and Aimmune’s ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune’s most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This press release concerns AR101, a product that is under clinical investigation, and AR201, a product that Aimmune expects will be under clinical investigation in 2019. Neither AR101 nor AR201 has been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). AR101 and AR201 are currently limited to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

Source: Aimmune Therapeutics, Inc.

Aimmune
Investors
Laura Hansen, Ph.D.
(650) 396-3814
lhansen@aimmune.com

Media
Alison Marquiss
(650) 376-5583
amarquiss@aimmune.com

KKR
Kristi Huller or Samantha Norquist
(212) 750-8300
media@KKR.com

Categories: News

Tags:

Triton has signed an agreement to invest in Deutsche Radiologie Holding

Triton

Frankfurt (Germany), 4 January 2019 – The Smaller Mid-Cap Fund (“TSM”) advised by Triton (“Triton”) has signed an agreement to invest in Deutsche Radiologie Holding (“DRH”), alongside with the current shareholders consisting of the owners of Tempus Capital and the management team. Terms of conditions are not disclosed.

DRH was founded in 2017 and offers radiologists and radiotherapists flexible and professional succession solutions. DRH is a strong and experienced partner for successful owners. The experienced team ensures a technically competent and reliable handover process and a long-term preservation of the owner’s work.

The Triton Smaller Mid-Cap Fund seeks to invest in mid-cap companies in the sectors industrials, business services, consumer and health. This transaction is the 7th investment since inception of the fund Mid 2017.

“Succession planning is a highly important topic for owners of small and mid-sized companies across all sectors and regions we operate in. DRH is addressing the increasing demand for succession solutions with a professional offering, tailor made to its target group. We are pleased to work with DRH, its management team and the owners of Tempus Capital on the way forward”, comments Andi Klein, TSM Investment Advisory Committee Member and Investment Advisory Professional to the Triton funds.

Steffen Dauster, CEO and founder of DRH, adds: “Given the large demand for flexible succession solutions in our area and our strong growth profile, we welcome Triton as a new partner. We are excited about the future prospects of DRH and the continued partnership with all our stakeholders.”

About Triton
The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe, focusing on businesses in the Industrial, Business Services and Consumer/Health sectors.

Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth. The 38 companies currently in Triton’s portfolio have combined sales of around € 13.1 billion and around 85,000 employees.

The Triton funds are advised by dedicated teams of professionals based in Germany, Sweden, Norway, Finland, Denmark, Italy, the United Kingdom, the United States, China, Luxembourg and Jersey.

For more information: www.triton-partners.com

About DRH
Deutsche Radiologie Holding was founded 2017. Headquartered in Frankfurt / Main, DRH accompanies radiological, nuclear medicine and radiotherapeutic practices on the path to succession planning as a financially strong investor and professional management partner. The team has many years of experience and extensive practical expertise in this field.

For more information: www.deutsche-radiologie.com

Press Contacts:

Triton
Marcus Brans
Phone: +49 69 921 02204

Deutsche Radiologie Holding
Edina Sabanovic
esabanovic@deutsche-radiologie.com

Categories: News

Tags:

SOPHIA GENETICS raises $77 million to accelerate the democratization of data-driven medicine

Endeavour

San Francisco, Jan. 4, 2019: SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data- Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco. Generation were joined by Idinvest Partners, a European leader in private equity, alongside existing investors including Balderton Capital and Alychlo.

SOPHiA GENETICS was founded in Switzerland and is now co-based in Lausanne and Boston. The company combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. Today, its universal platform, SOPHiA AI, is utilized by more than 850 hospitals across 77 countries and has already supported the diagnosis of over 300,000 patients. The platform enables healthcare professionals to make sense of complex genomic and radiomic data through advanced analysis in order to better diagnose and treat patients, both for oncology and hereditary disorders.

With the new funding round, SOPHiA GENETICS has now raised a total of $140 million. This latest investment will allow the company to further grow the global community of hospitals using its technology. In particular, SOPHiA GENETICS will continue adding talent to reinforce its rapidly expanding presence in the US.

“Generation are delighted to partner with SOPHiA GENETICS. We believe that leveraging genetic sequencing and advanced digital analysis will enable a more sustainable healthcare system. SOPHiA GENETICS is a leader in the preventive and personalized medicine revolution, enabling the development of targeted therapeutics, thereby vastly improving health outcomes” said Lilly Wollman, co-head of Generation’s Growth Equity team. “We admire SOPHiA GENETICS not just for its differentiated analytics capability across genomic and radiomic data, but also for its exceptional team and culture”.

“Since we founded the company, our goal has been to help make the global healthcare system more sustainable. By helping clinical researchers leverage their expertise and work together as a community, patients all over the world can receive equal access to better care. Generation Investment Management and SOPHiA GENETICS are guided by the same belief. With Generation’s support, we will enable the more rapid adoption of Data-Driven Medicine technology in healthcare for the benefit of patients worldwide,” commented Dr. Jurgi Camblong, CEO and Founder of SOPHiA GENETICS.

Categories: News

Tags: